Some implementations may involve presenting a feature game round that includes a hold and spin stage and a free game stage. The free game stage may be presented after the hold and spin stage. In some examples, the number of free game instances may correspond to the number of configurable symbols accumulated by the conclusion of the hold and spin stage. In some instances, at least one of the configurable symbols accumulated by the conclusion of the hold and spin stage may indicate a modifier for the free game stage. The modifier may correspond with a modification of one or more reels that are used during a free game instance. In some examples, at least one of the configurable symbols accumulated during the hold and spin stage may indicate a multiplier for an award that is determined during a first free game instance.

Some implementations may involve presenting a feature game round that includes a hold and spin stage and a free game stage. The free game stage may be presented after the hold and spin stage. In some examples, the number of free game instances may correspond to the number of configurable symbols accumulated by the conclusion of the hold and spin stage. In some instances, at least one of the configurable symbols accumulated by the conclusion of the hold and spin stage may indicate a modifier for the free game stage. The modifier may correspond with a modification of one or more reels that are used during a free game instance. In some examples, at least one of the configurable symbols accumulated during the hold and spin stage may indicate a multiplier for an award that is determined during a first free game instance.

Disclosed herein are in vitro methods of multiple staining and slide preparation for a cytopathological sample, such as a urine sample. These methods enable simultaneous staining of biomarkers and cytopathological stains to greatly enhance confidence in identifying atypical cells such as cancer cells. Also disclosed herein are methods of using said staining and preparation methods for the detection of bladder cancer using urine samples from a patient. These methods offer increased sensitivity and specificity over conventional bladder cancer detection methods. Also disclosed herein are the urinary exfoliated cells stained according to the methods provided herein.

An object of the present invention is to provide a hemoglobin measurement reagent and measurement method that allow for more accurate measurement of the amount of hemoglobin by suppressing a decrease in a measured value of hemoglobin triggered by the addition of haptoglobin. The reagent for measuring hemoglobin of the present invention includes: an insoluble carrier immobilizing an anti-hemoglobin antibody; and an insoluble carrier immobilizing an anti-haptoglobin antibody. The method for measuring hemoglobin in a specimen of the present invention includes: a step (1) of mixing a specimen with haptoglobin and forming a hemoglobin-haptoglobin complex to obtain a sample containing the hemoglobin-haptoglobin complex; and a step (2) of bringing the sample obtained in the step (1) into contact with the insoluble carrier immobilizing an anti-hemoglobin antibody and the insoluble carrier immobilizing an anti-haptoglobin antibody to cause immunoagglutination.

A biochip is described having a substrate that has disposed on a surface at least one spot containing a complex between a solid carrier modified by a reactive group and a substance to be immobilized that has been modified via a spacer by a group that reacts with the reactive group. A method for producing the biochip and a method for detecting a target substance using the biochip are also described.

It is described a silica nanoparticle comprising: a) a silicate network core with a diameter in a range from 10 nm to 500 nm, preferably from 20 nm to 250 nm, wherein at least a luminophore (dye) is confined in the said silicate network core, or covalently linked to the silicate network of the core because said luminophore (dye) has an anchoring moiety able to form at least a covalent link with the silicate network core, b) a shell layer over the silicate network core a) incorporating dye/s, said shell layer b) with a thickness from 0.5 to 7 nm, preferably from 0.5 to 6 nm, more preferably from 1 to 5 nm, comprising colloidal stabilizer agent/s, selected from the group comprising: sterical or electrostatic antifouling agents or polyether antifouling agents.

Some implementations may involve presenting a feature game round that includes a hold and spin stage and a free game stage. The free game stage may be presented after the hold and spin stage. In some examples, the number of free game instances may correspond to the number of configurable symbols accumulated by the conclusion of the hold and spin stage. In some instances, at least one of the configurable symbols accumulated by the conclusion of the hold and spin stage may indicate a modifier for the free game stage. The modifier may correspond with a modification of one or more reels that are used during a free game instance. In some examples, at least one of the configurable symbols accumulated during the hold and spin stage may indicate a multiplier for an award that is determined during a first free game instance.

A particle including a polymer which has a repeating unit derived from a vinyl-based monomer. The particle has a specific structure containing a carboxy group, and a surface of the particle contains a water-soluble polymer.

Described herein are methods, systems and kits for conducting an assay for one or more analytes of interest in a sample. In one aspect, a method is provided for conducting a multiplexed binding assay for a plurality of analytes of interest in a sample. In one aspect, the assay includes an analyte binding step and a detection step. In one aspect, the analyte binding step is separated from the detection step.

The present invention relates to a Point-of-Care in vitro diagnostic (IVD) medical device for quantitative multi-analyte immunoassay's, such as SR-ECLIA, spatially resolved ECL immunoassay, including a detachable single-use analytical cartridge and a mobile base station, wherein the cartridge is adapted to receive a sample to analyse through a sample inlet port (201) and to mix it with first biomarker(s)-specific ligands L1 coupled with an electrochemiluminescent detection label. and comprises a sensor unit including electrodes pre-functionalized with second biomarker(s)-specific ligands L2 with which the mixed solution is reacted, to form a sandwich immunoassay complex, wherein each of the first biomarker(s)-specific ligands L1 can be immobilized at a different, separate location on the conductive electrode surface and being adapted to apply a potential to the pre-functionalized electrodes and trigger an ECL reaction between the reagents producing an ECL signal pattern to be acquired by a detector unit (130), and wherein the mobile base station is adapted to receive the cartridge via a cartridge interface and to apply a potential to the pre-functionalized electrodes to trigger an ECL reaction between the reagents in the sensor unit (207). and comprises a detector unit (130) for detecting said ECL signal pattern generated in the sensor unit (207) of the cartridge (101), being connected to the sensor unit (207) via an optic path (132) crossing a first window (133) on the station interfacing with the cartridge (101) via a second window on the cartridge (134).